Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open-Label Study to Evaluate the Hematopoietic Stem Cell Mobilization of TG-0054 Combined With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease

Next Previous
Trial Profile

A Phase II, Open-Label Study to Evaluate the Hematopoietic Stem Cell Mobilization of TG-0054 Combined With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Burixafor (Primary) ; Granulocyte colony-stimulating factors
  • Indications Stem cell mobilisation
  • Focus Therapeutic Use
  • Sponsors GPCR Therapeutics; TaiGen Biotechnology

Most Recent Events

  • 05 Feb 2026 Primary endpoint (the total number of hematopoietic stem cells (HSCs) collected within first four leukapheresis sessions following treatment) has been met, according to an Exicure media release.
  • 05 Feb 2026 According to an Exicure media release, the company announced the publication of results from a prior Phase 2 clinical study evaluating burixafor (GPC-100/TG-0054), a highly selective CXCR4 inhibitor, in the journal Annals of Hematology.
  • 05 Feb 2026 Results published in an Exicure Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top